Package leaflet: Information for the patient
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
-Keep this leaflet. You may need to read it again.
-If you have any further questions, ask your doctor, or a physician experienced in the medical treatment of blood cancer.
-If you get any side effects, talk to your doctor, or a physician experienced in the medical treatment of blood cancer. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1.What Zalmoxis is and what it is used for
2.What you need to know before you are given Zalmoxis
3.How Zalmoxis is given to you
4.Possible side effects
5.How to store Zalmoxis
6.Contents of the pack and other information
1.WHAT ZALMOXIS IS AND WHAT IT IS USED FOR
Zalmoxis consists of white blood cells called T cells that are obtained from the donor. These cells will be genetically modified by introducing a “suicide” gene
Zalmoxis is intended for use in adults with certain tumours of the blood known as
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ZALMOXIS
Do not use Zalmoxis:
-If you are allergic to the active substance or any of the ingredients of this medicine (listed in section 6).
-If, before infusion, the value of CD3+ lymphocytes in your tests is equal to or more than 100 per
-If you suffer from
Warnings and precautions
Zalmoxis is a patient specific product and should under no circumstances be administered to other patients.
Your doctor will closely supervise the treatment therapy. You should tell your doctor before using Zalmoxis if:
-You suffer from infections requiring administration of ganciclovir (GCV) or valganciclovir (VCV) (antiviral) at the time of infusion. In this case treatment with Zalmoxis should be delayed until 24 hours after the end of the antiviral therapy.
-You suffer from
-If you are taking medicines to suppress your immune system or you are taking
-If you have previously experienced any adverse reaction following Zalmoxis administration and this has not been resolved within 30 days after its occurrence.
When Zalmoxis cannot be given
In some cases you may not be able to receive a scheduled infusion of Zalmoxis. This may be because of manufacturing issues.
In such cases your physician will be informed and may still consider preferable to give the treatment or may select an alternative treatment for you.
Children and adolescents
Currently, no data are available for these patients. The use of Zalmoxis is not recommended for children and adolescents under the age of 18.
Other medicines and Zalmoxis
No interaction studies have been performed.
Please inform your doctor if you are taking, have recently taken or might take any other medicines.
The safe use of Zalmoxis has not been demonstrated during pregnancy and
Women of childbearing potential have to use effective contraception during and up to 6 months after treatment with Zalmoxis.
If you are pregnant or
Driving and using machines
Zalmoxis should not have any effects on your ability to drive and use machines. However, you should pay attention to your overall status when considering performing tasks that require judgment, motor or cognitive skills.
Zalmoxis contains sodium
3.HOW ZALMOXIS IS GIVEN TO YOU
Zalmoxis can only be prescribed and administered in a hospital by a doctor or a nurse who is trained in administering this medicine. Practical information for handling and administration of Zalmoxis for the doctor or nurse can be found at the end of this leaflet.
Zalmoxis has been manufactured specifically for you and cannot be administered to any other patient. The amount of cells to be administered depends on your body weight. The dose corresponds to 1 ± 0.2 x 107 cells/kg.
Zalmoxis is given intravenously (into a vein) as a drip infusion over approximately
If you receive more Zalmoxis than you should
As this medicine is prescribed by a doctor, each dose is prepared for you only and each preparation consists of a single dose. It is unlikely that you will be given too much.
If you forget to use Zalmoxis
This medicine is prescribed by a doctor and given in a hospital under strict survelliance and predetermined schedule so that you cannot forget your dose.
If you have any further questions on the use of this medicine, ask your doctor.
4.POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects may be serious and may lead to hospitalization.
If you have any questions about symptoms or side effects, or if any symptoms concern you
→ Talk immediately to your doctor.
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
-Intestinal haemorrage (bleeding in the gut)
-Hepatic failure (liver malfunction)
-Febrile neutropenia (fever associated with reduction of the number of white blood cells)
-Decreased haemoglobin (reduction of the number of red blood cells)
-Decreased platelet count (reduction of the number of platelets in the blood)
-Bronchitis (lung infection)
Reporting of side effects
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5.HOW TO STORE ZALMOXIS
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the container. The expiry date refers to the last day of that month.
Store in liquid nitrogen vapour.
The infusion solution should be used immediately after thawing. Maximum time elapsed from thawing and infusion is 2 hours at room temperature (15 °C – 30 °C).
The package is checked for the presence of any abnormality in the outer box and the label is checked for patient/donor correspondance.
Any unused medicine or waste should be disposed of as biological hazard material containing genetically modified organisms and in accordance with local requirements.
The hospital staff are responsible for the correct storage of the product both before and during its use, as well as for correct disposal.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Zalmoxis contains
The active substance consists of allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase
Each bag contains a volume of
The other ingredients are sodium chloride, human serum albumin and dimethyl sulfoxide (see section 2).
What Zalmoxis looks like and contents of the pack
Zalmoxis is a cell dispersion for infusion appearing as opaque,
Zalmoxis is supplied as one individual treatment dose in a
Marketing Authorisation Holder and Manufacturer
MolMed SpA Via Olgettina 58 20132 Milano Italy
This leaflet was last revised in
This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.
The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.
The following information is intended for healthcare professionals only:
Practical information for medical or healthcare professionals on the handling and administration of Zalmoxis.
Zalmoxis must be administered under the supervision of a physician experienced in haematopoietic stem cell transplantation for haematological malignacies.
It is important that you read the entire content of this procedure prior to administering Zalmoxis.
Dose and course of treatment
One bag contains donor T cells genetically modified to express
The course of treatment is a maximum of four infusions at approximately one month intervals. The decision to proceed with a new treatment depends on the immune reconstitution status of the patient achieved when a circulating T lymphocyte count is equal to or more than 100 per µL.
Before handling or administering Zalmoxis
•Zalmoxis is shipped directly to the medical facility where the infusion will be administered. The shipping is performed in liquid nitrogen vapour. The bag is put in a second bag (intermediate container) and this one is placed in an aluminium box (outer container). The whole package is secured in a liquid nitrogen container designed to maintain the appropriate transportation and storage temperature until the time of infusion. If the medicinal product is not immediately prepared for infusion, transfer the bag in liquid nitrogen vapour. Do not irradiate.
•Zalmoxis is prepared from human blood of a specific donor and it consists of genetically modified cells. Donors are tested for transmissible infectious agents in line with applicable local requirements. However, the risk of transmitting infectious viruses to healthcare professionals
cannot be totally excluded. Accordingly, healthcare professionals should take appropriate precautions (e.g. wearing gloves and glasses) when handling Zalmoxis.
•The outer and intermediate package should be checked to verify the product and
What to check before infusion
•Check that the Certificate of Analysis containing the patient identifiers, expiry date and approval for infusion has been received from the Marketing Authorization Holder.
•Check that the patient identity matches the essential and unique patient information reported on the Zalmoxis bag and on the Certificate of Analysis.
•Once the patient is prepared for infusion, inspect the Zalmoxis bag for integrity. The bag should appear as an opaque,
•Put the bag into two plastic envelopes (double envelopment) to avoid direct contact with water.
•While holding the top of the envelope bag out of the water, put it in a 37±1°C water bath being careful not to allow water to penetrate the seal. If leakage occurs during thawing, do not use the product.
•When completely thawed, remove the Zalmoxis bag out from the double envelopment, dry it off and disinfect the outside.
•Proceed with the infusion as quickly as possible, avoiding keeping the bag in the water bath after thawing.
•The entire volume of the bag must be infused. The recommended infusion time is around
After the infusion
•At the end of infusion, wash the bag 2 or 3 times with a physiological solution using a sterile technique, in order to completely administer Zalmoxis.
•Upon completion of washing, the patient specific label on the bag should be removed and adhered to the patient specific file.
•The cryobag and any unused product or waste material contains genetically modified organisms and should be disposed of in accordance with local requirements.
Do not infuse Zalmoxis if
•You have not received the Certificate of Analysis.
•The Certificate of Analysis is marked as rejected.
•The expiry date has passed.
•The unique patient information on the infusion bag does not match that of the scheduled patient.
•The product integrity has been breached in anyway.
Shelf life and special precautions for storage
•Zalmoxis has a shelf life of 18 months when stored in liquid nitrogen vapour.
•Zalmoxis must be used be immediately after removal from the shipping container. If not used immediately, transfer the Zalmoxis bag from the shipping container to liquid nitrogen vapour.
•Shelf life after thawing is of 2 hours.
Conclusions on the granting of the conditional marketing authorisation and similarity presented by the European Medicines Agency
Conclusions presented by the European Medicines Agency on:
•Conditional marketing authorisation
The CHMP having considered the application is of the opinion that the